Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 15/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432974 | 0.95 | SLC2A1 (0.60) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL1430932 | 0.86 | SLC2A3 (0.56) | SLC2A1MEN1KMT2AKDM4EGABRB2 | |
| SCHEMBL2227900 | 0.85 | KDM4E (0.67) | SLC2A1KDM4EHTTGABRB2 | |
| SCHEMBL1433352 | 0.83 | SLC2A1 (0.65) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL2275461 | 0.81 | SMN1; SMN2 (0.56) | SLC2A1KDM4EHTTGABRA2GABRB2 | |
| SCHEMBL1432954 | 0.80 | ALDH1A1 (0.56) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL2222798 | 0.79 | SLC2A1 (0.61) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL1430426 | 0.78 | SLC2A1 (0.59) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL1430501 | 0.78 | SLC2A1 (0.61) | SLC2A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL1433233 | 0.78 | SLC2A1 (0.60) | SLC2A1MEN1KMT2AKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SLC2A1 2033/4885MEN1 1720/4885KMT2A 3191/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SLC2A1 2033/4885MEN1 1720/4885KMT2A 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.